Análisis de la acción Unicycive Therapeutics Inc (UNCY)

Análisis de IA of Unicycive Therapeutics Inc (UNCY)

Mantener

Unicycive Therapeutics Inc is currently not a strong buy due to its recent performance and technical indicators. The current price is $3.49, which is significantly below its 52-week high of $8.74, indicating a potential for recovery but also substantial risk. The RSI is at 32.171, suggesting the stock is oversold, but the recent 5-day change is -2.51%, reflecting continued downward pressure. The forward P/E ratio is 2.0661, which could indicate potential value, but the company has a negative net income and gross profit in recent quarters, with a net income of -21,525,000 USD in Q4 2024 and -6,447,000 USD in Q2 2025. The main risk is the ongoing FDA issues, as highlighted by the recent news of executives being sued for failing to ensure compliance, which could further impact stock performance.

Métricas de valoración

El PER previsto actual de Unicycive Therapeutics Inc (UNCY) es 1.99, frente a su media de 5 años de 0.45.

PER previsto

Valor razonable

Media 5A P/E

0.45

P/E actual

1.99

Sobrevalorada

7.03

Infravalorada

-6.13

EV/EBITDA previsto

Valor razonable

Media 5A EV/EBITDA

-6545.04

EV/EBITDA actual

0.00

Sobrevalorada

23017.88

Infravalorada

-36107.96

Precio/ventas previsto

Valor razonable

Media 5A P/S

4.06

P/S actual

0.74

Sobrevalorada

15.58

Infravalorada

-7.46

Escenarios de precio de Alphio AI para UNCY

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%UNCY

$5.26

Precio del escenario

B

Base

Base · 50%UNCY

$4.33

Precio del escenario

B

Bajista

Bajista · 25%UNCY

$3.97

Precio del escenario

Ballenas con UNCY en cartera

L

Logos Global Management, L.P.

+ Con en carteraUNCY

+20.59%

Rentabilidad a 3 meses

Preguntas frecuentes sobre UNCY, respondidas por Alphio AI

Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Unicycive Therapeutics Inc is currently not a strong buy due to its recent performance and technical indicators. The current price is $3.49, which is significantly below its 52-week high of $8.74, indicating a potential for recovery but also substantial risk. The RSI is at 32.171, suggesting the stock is oversold, but the recent 5-day change is -2.51%, reflecting continued downward pressure. The forward P/E ratio is 2.0661, which could indicate potential value, but the company has a negative net income and gross profit in recent quarters, with a net income of -21,525,000 USD in Q4 2024 and -6,447,000 USD in Q2 2025. The main risk is the ongoing FDA issues, as highlighted by the recent news of executives being sued for failing to ensure compliance, which could further impact stock performance.